See also stories tagged with Drug discovery
More than 100,000 people are awaiting an organ transplant in the United States, with a new candidate added to the list every 10 minutes. Even if the transplant is carried out successfully, recipients must take immunosuppressive ...
The decades-old scientific quest to create brand-new proteins has been turbocharged in the era of artificial intelligence.
Scientists have long been fascinated by two promising classes of antibiotics that disable RNA polymerase (RNAP). They knew that these drugs could grind gene expression to a halt in several pathogens, including the bacterium ...
Every living cell, from the simplest bacterium to a human neuron, relies on the same basic machinery to read, interpret, and use its DNA. This molecular machinery is so fundamental that life as we know it cannot exist without ...
For most healthy people, Cryptococcus is an unnoticed infection. The immune system walls it off in the lungs and keeps it dormant for life. But in patients undergoing cancer chemotherapy, recovering from an organ transplant, ...
In a world first, scientists led by a team from Stanford University have created 16 viable viruses that do not exist in nature and were designed by AI. Their experiment, which is published in Science, could help in the fight ...
Investigators at Dana-Farber Cancer Institute have developed a platform for systematically discovering molecular glues that could become protein degradation drug candidates. The platform could help drug developers dramatically ...
Nanoscience, which studies small objects, has a big problem. According to a team of scientists at the National Institute of Standards and Technology (NIST), the field confronts a pervasive data analysis error that can give ...
Cancer cells have a voracious appetite for sugar—using it to fuel their rapid growth. This is why many scientists have tried to develop drugs that block cancer cells' metabolism by cutting off their sugar supply.
A research team from AIST, the Institute of Science Tokyo, and Ritsumeikan University has demonstrated that the phase behavior of histone–DNA condensates depends on the site of histone acetylation.
